Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
Authors
Van K. Morris II
NRG Oncology, and University of Texas-MD Anderson Cancer Center, Houston, TX
Van K. Morris II, Greg Yothers , Scott Kopetz , Samuel A. Jacobs , Peter C. Lucas , Atif Iqbal , Patrick M Boland , Dustin A. Deming , Aaron James Scott , Howard John Lim , Theodore S. Hong , Norman Wolmark , Thomas J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT04068103
DOI
10.1200/JCO.2022.40.4_suppl.TPS233
Abstract #
TPS233
Poster Bd #
P2
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
First Author: Van K. Morris II
Poster
2020 ASCO Virtual Scientific Program
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
First Author: Van K. Morris II
Poster
2023 ASCO Annual Meeting
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
First Author: Van K. Morris II
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
First Author: Van K. Morris II